Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

is increase was tempered by the non- recurrence of severance costs incurred in the second quarter of 2007, lower expenses related to the sales and marketing of Megace(R) ES and lower bonus and stock-based compensation.

2008 Financial Guidance

Par has adjusted its previously announced guidance for full-year 2008 earnings per diluted share from continuing operations of $0.65-$0.85 to ($0.06)-$0.38 reflecting the pricing pressure on the Company's generic business experienced in the second quarter, a challenging reimbursement environment for Megace(R) ES and higher legal costs. The Company's projections are based on its results for the first six months of 2008 and the impact of recent new product launches, as well as management's estimates regarding the impact of product competition on existing products and anticipated legal costs. This EPS range excludes anticipated pre-launch spending and milestone payments in support of Strativa's business strategy and includes the estimated impact of three potential new generic product launches (i.e., sumatriptan kits, clonidine, and certain strengths of risperidone ODT) with an expected fully diluted EPS impact of $0.24-$0.39. These estimates are, of course, subject to future developments, not all of which may be anticipated at this time.

Conference Call

Par has scheduled a conference call for Friday, August 8 at 9:00 am ET to discuss results for the second quarter of 2008. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at http://www.parpharm.com. The dial-in numbers for the conference call will be 888-713-4213 for domestic callers and 617-213-4865 for international callers. The passcode is 56885024. A replay of the conference call will be available for two weeks approximately one hour after the call. The dial-in numbers for the replay are 888-2
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... of Arts and Sciences has received a major ... , Mathew M. Maye, associate professor of chemistry, ... the National Science Foundation (NSF). The award supports ... the results of which may impact gas storage, ... , Maye,s approach is novel, in that he ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Sleep ... quality are closely correlated with depression. According to ... Health: "About three quarters of depressed patients ... about 40% of young depressed adults and 10% ... The symptoms cause huge distress, have a major ...
(Date:7/20/2014)... (PRWEB) July 20, 2014 NSG ... quartz glass optics, and spectrophotometer calibration ... years, NSG has released many products that have ... product has been their solid-state calibration standards. , ... standards since their release in 2008. NSG ...
Breaking Biology Technology:Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3
... Switzerland, May 16 Arpida Ltd.,(SWX: ARPN) today announced ... for review the New Drug Application (NDA) for,intravenous iclaprim ... (cSSSI). Arpida completed the submission of the NDA to,the ... ten month review to,the iclaprim NDA and has established ...
... Million - ... - Gross Profit Up; Net Loss Down -, TUSTIN, ... a vertically integrated specialty pharmaceutical company headquartered,in Tustin, California, with ... subsidiary Jade Pharmaceutical Inc. (JPI),the Company engages in the research, ...
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
Cached Biology Technology:Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 3AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3
(Date:7/21/2014)... cheating in science are among the topics to ... experts in Montreal at the three International Union ... to August 1, 2014. Some 2,000 participants from ... 14th International Congress of Bacteriology and Applied Microbiology, ... Microbiology, and the 16th International Congress of Virology. ...
(Date:7/21/2014)... in areas across Riau province on Sunday, July 20, ... a decline in rainfall. The number of detected ... had been reported one day prior, which had reached ... six regencies and municipalities, most of which were in ... it creates could potentially spread via winds to Malaysia ...
(Date:7/21/2014)... that uses extracts from seeds of Moringa oleifa trees ... 90% to 99%. The hardy trees that are drought ... Asia, and Latin America. , The protocol, which is ... review, is low-cost and efficient, making it especially useful ... who are presently drinking highly turbid and contaminated water. ...
Breaking Biology News(10 mins):Montreal hosts International Union of Microbiology Societies congresses 2
... must address ecological threats, a top international scientific meeting ... the planet,s natural limits in a striking parallel to ... a subprime loan," Dr. Johan Rockstrm of the Stockholm ... risks of both kinds of crises in the future. ...
... a multi-year $1 million sponsored research agreement with ... the maker of Smart Balance buttery spread and ... cholesterol through a patented blend of natural vegetable ... entered into a collaboration and license to develop ...
... 6, 2008, Cambridge, UK ,Discussion of a man,s background, ... and The City episodes in the future, it could ... Risk of developing type 2 diabetes and metabolic ... this background has in turn been influenced by environment and ...
Cached Biology News:Top scientific meeting urges coordinated response to economic and environmental crises 2Brandeis and Smart Balance team up to advance heart-healthy research 2Coping and copulation behavior may help calculate diabetes risk 2